<p>MiMedx Group（纳斯达克代码：MDXG - 获取免费报告）于周三发布了其财报。公司报告本季度每股收益（EPS）为 0.14 美元，超出分析师一致预期的 0.09 美元，超出幅度为 0.05 美元，FiscalAI 报道。MiMedx Group 的净利润率为 10.38%，股本回报率为 27.19%。公司本季度的收入为 1.181 亿美元，而分析师预期为 1.0678 亿美元。</p>
<p>以下是 MiMedx Group 电话会议的主要要点：</p>
<ul>
<li>MiMedx 报告了创纪录的 2025 年业绩——全年净销售额为 <strong>4.19 亿美元</strong>（+20%），第四季度净销售额为 <strong>1.18 亿美元</strong>（+27%），调整后的 EBITDA 约为 <strong>1.06 亿美元</strong>，净现金余额接近 <strong>1.48 亿美元</strong>，增强了盈利能力和流动性。</li>
<li>Medicare 报销重置（价格上限约为 <strong>127 美元/cm²</strong>）和 WISeR 事先授权的实施导致了短期干扰、较低的平均销售价格和较慢的伤口处理量；管理层预计 2026 年收入为 <strong>3.4 亿至 3.6 亿美元</strong>，调整后的 EBITDA 在中高十位数。</li>
<li>外科业务是明确的增长驱动因素——外科销售在第四季度增长约 25%，全年增长 20%，得益于增加的商业资源、新推出的产品如 <strong>AMNIOFIX 甲状腺保护膜</strong> 以及最近获得许可的补充外科产品。</li>
<li>强大的资本灵活性：公司持有大量现金，董事会授权在两年内进行 <strong>1 亿美元的股票回购计划</strong>，同时对有纪律的并购持开放态度，以加速战略。</li>
<li>临床证据推动：<strong>EPIEFFECT 随机对照试验</strong> 几乎完全招募，预计很快会有结果和出版物，并计划进行 <strong>CHORIOFIX</strong> 的随机对照试验，强化公司的基于证据的定位。</li>
</ul>
<h2>MiMedx Group 股票下跌 1.3%</h2>
<p>MDXG 周三下跌 0.07 美元，报 5.28 美元。该公司的股票交易量为 739,895 股，而其平均交易量为 960,905 股。公司市值为 7.8198 亿美元，市盈率为 19.56，贝塔值为 1.59。MiMedx Group 的 52 周低点为 4.89 美元，52 周高点为 8.46 美元。公司流动比率为 3.95，当前比率为 4.41，债务与股本比率为 0.07。该股票的 50 日移动平均线为 5.82 美元，200 日移动平均线为 6.61 美元。</p>
<h2>机构资金流入和流出</h2>
<p>几家大型投资者最近调整了对 MDXG 的持股。Nantahala Capital Management LLC 在第三季度收购了 MiMedx Group 的新股份，价值约为 10,237,000 美元。Marshall Wace LLP 在第四季度将其在 MiMedx Group 的持股增加了 864.9%。Marshall Wace LLP 现在拥有 1,381,288 股公司股票，价值 9,351,000 美元，此前在该期间内又收购了 1,238,132 股。Disciplined Growth Investors Inc. MN 在第三季度将其在 MiMedx Group 的持股增加了 283.0%。Disciplined Growth Investors Inc. MN 现在拥有 1,383,451 股公司股票，价值 9,656,000 美元，此前在上个季度又收购了 1,022,202 股。Millennium Management LLC 在第一季度将其在 MiMedx Group 的持股增加了 93.9%。Millennium Management LLC 现在拥有 1,230,984 股公司股票，价值 9,355,000 美元，此前在该期间内又收购了 596,016 股。最后，Ameriprise Financial Inc.在第二季度将其在 MiMedx Group 的持股增加了 5,332.5%。Ameriprise Financial Inc.现在拥有 559,058 股公司股票，价值 3,416,000 美元，此前在该期间内又收购了 548,767 股。机构投资者和对冲基金持有公司 79.15% 的股份。</p>
<h2>分析师评级变动</h2>
<p>几位分析师最近对该公司发布了报告。花旗集团在周一的研究报告中开始覆盖 MiMedx Group。他们对该股票给予了 “市场表现优于大盘” 的评级。瑞穗证券在 12 月 17 日的研究报告中将 MiMedx Group 的目标价从 12.00 美元下调至 10.00 美元，并对该股票给予了 “表现优于大盘” 的评级。Citizens Jmp 在周一的研究报告中开始覆盖 MiMedx Group。他们对该公司给予了 “市场表现优于大盘” 的评级，目标价为 10.00 美元。瑞银集团在周一的研究报告中对 MiMedx Group 设定了 10.00 美元的目标价。最后，华尔街 Zen 在 11 月 2 日的报告中将 MiMedx Group 的股票评级从 “买入” 上调至 “强力买入”。五位股票研究分析师对该股票给予了买入评级，一位分析师对该公司给予了持有评级。根据 MarketBeat，该股票的共识评级为 “适度买入”，平均目标价为 9.60 美元。</p>
<p><strong>查看我们最新的 MiMedx Group 股票报告</strong></p>
<h2>MiMedx Group 公司简介</h2>
<p>（获取免费报告）</p>
<p>MiMedx Group, Inc 是一家生物制药公司，专注于开发、制造和营销源自人类胎盘组织的再生生物材料产品。公司的核心使命是利用羊膜和绒毛膜中的细胞外基质和生长因子来支持伤口愈合和外科应用。MiMedx 的产品线利用专有的净化工艺，旨在保留原生组织特性，同时确保无菌和安全。</p>
<p>MiMedx 的主要产品包括以 EpiFix®和 AmnioFix®等品牌命名的羊膜/绒毛膜同种异体移植物，适用于急性和慢性伤口的治疗，包括糖尿病足溃疡、静脉性腿部溃疡和手术部位修复。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票比 MiMedx Group 更好</li>
<li>华尔街害怕的黄金图表……</li>
<li>美国 1776 年再次发生</li>
<li>这让我感到愤怒</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 MiMedx Group 吗？</h2>
<p>在考虑 MiMedx Group 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 MiMedx Group 并不在名单上。</p>
<p>虽然 MiMedx Group 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

MDXG

<p>MiMedx Group（纳斯达克代码：MDXG）报告的季度每股收益为 0.14 美元，超出预期的 0.09 美元，超出幅度为 0.05 美元。该公司实现了 1.181 亿美元的收入，超过了 106.78 万美元的预期。MiMedx 的净利润率为 10.38%，股本回报率为 27.19%，同时宣布了一项 1 亿美元的股票回购计划。尽管股价下跌 1.3% 至 5.28 美元，但机构投资者显著增加了持股比例。分析师维持 “适度买入” 的共识评级，平均目标价为 9.60 美元</p>

<p>MiMedx Group (NASDAQ:MDXG - Get Free Report) released its earnings results on Wednesday. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.05, FiscalAI reports. MiMedx Group had a net margin of 10.38% and a return on equity of 27.19%. The company had revenue of $118.10 million for the quarter, compared to analyst estimates of $106.78 million.</p>
<div class="lb-trans"><p>MiMedx Group（纳斯达克代码：MDXG - 获取免费报告）于周三发布了其财报。公司报告本季度每股收益（EPS）为 0.14 美元，超出分析师一致预期的 0.09 美元，超出幅度为 0.05 美元，FiscalAI 报道。MiMedx Group 的净利润率为 10.38%，股本回报率为 27.19%。公司本季度的收入为 1.181 亿美元，而分析师预期为 1.0678 亿美元。</p>
</div><p>Here are the key takeaways from MiMedx Group's conference call:</p>
<div class="lb-trans"><p>以下是 MiMedx Group 电话会议的主要要点：</p>
</div><ul>
<li>MiMedx reported record 2025 results — full‑year net sales of <strong>$419M</strong> (+20%), Q4 net sales of <strong>$118M</strong> (+27%), adjusted EBITDA ~ <strong>$106M</strong> and a net cash balance near <strong>$148M</strong>, strengthening profitability and liquidity.</li>
<li>The Medicare reimbursement reset (price cap ~$127/cm²) and WISeR prior‑auth implementation have caused near‑term disruption, lower ASPs and slower wound volumes; management guides 2026 revenue of <strong>$340–360M</strong> with adjusted EBITDA in the mid‑to‑high teens.</li>
<li>The surgical franchise is a clear growth driver — surgical sales grew ~25% in Q4 and 20% for the year, supported by increased commercial resources, new launches like <strong>AMNIOFIX Thyroid Shield</strong>, and recently licensed complementary surgical products.</li>
<li>Strong capital flexibility: the company holds substantial cash and the board authorized a <strong>$100M share repurchase program</strong> over two years while remaining open to disciplined M&amp;A to accelerate strategy.</li>
<li>Clinical evidence push: the <strong>EPIEFFECT randomized controlled trial</strong> is nearly fully enrolled with results and publications expected soon, and an RCT for <strong>CHORIOFIX</strong> is planned, reinforcing the company's evidence‑based positioning.</li>
</ul>
<div class="lb-trans"><ul>
<li>MiMedx 报告了创纪录的 2025 年业绩——全年净销售额为 <strong>4.19 亿美元</strong>（+20%），第四季度净销售额为 <strong>1.18 亿美元</strong>（+27%），调整后的 EBITDA 约为 <strong>1.06 亿美元</strong>，净现金余额接近 <strong>1.48 亿美元</strong>，增强了盈利能力和流动性。</li>
<li>Medicare 报销重置（价格上限约为 <strong>127 美元/cm²</strong>）和 WISeR 事先授权的实施导致了短期干扰、较低的平均销售价格和较慢的伤口处理量；管理层预计 2026 年收入为 <strong>3.4 亿至 3.6 亿美元</strong>，调整后的 EBITDA 在中高十位数。</li>
<li>外科业务是明确的增长驱动因素——外科销售在第四季度增长约 25%，全年增长 20%，得益于增加的商业资源、新推出的产品如 <strong>AMNIOFIX 甲状腺保护膜</strong> 以及最近获得许可的补充外科产品。</li>
<li>强大的资本灵活性：公司持有大量现金，董事会授权在两年内进行 <strong>1 亿美元的股票回购计划</strong>，同时对有纪律的并购持开放态度，以加速战略。</li>
<li>临床证据推动：<strong>EPIEFFECT 随机对照试验</strong> 几乎完全招募，预计很快会有结果和出版物，并计划进行 <strong>CHORIOFIX</strong> 的随机对照试验，强化公司的基于证据的定位。</li>
</ul>
</div><h2>MiMedx Group Stock Down 1.3%</h2>
<div class="lb-trans"><h2>MiMedx Group 股票下跌 1.3%</h2>
</div><p>MDXG traded down $0.07 on Wednesday, reaching $5.28. The company's stock had a trading volume of 739,895 shares, compared to its average volume of 960,905. The company has a market capitalization of $781.98 million, a price-to-earnings ratio of 19.56 and a beta of 1.59. MiMedx Group has a fifty-two week low of $4.89 and a fifty-two week high of $8.46. The company has a quick ratio of 3.95, a current ratio of 4.41 and a debt-to-equity ratio of 0.07. The stock has a 50 day moving average of $5.82 and a two-hundred day moving average of $6.61.</p>
<div class="lb-trans"><p>MDXG 周三下跌 0.07 美元，报 5.28 美元。该公司的股票交易量为 739,895 股，而其平均交易量为 960,905 股。公司市值为 7.8198 亿美元，市盈率为 19.56，贝塔值为 1.59。MiMedx Group 的 52 周低点为 4.89 美元，52 周高点为 8.46 美元。公司流动比率为 3.95，当前比率为 4.41，债务与股本比率为 0.07。该股票的 50 日移动平均线为 5.82 美元，200 日移动平均线为 6.61 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several large investors have recently modified their holdings of MDXG. Nantahala Capital Management LLC acquired a new stake in shares of MiMedx Group during the third quarter worth about $10,237,000. Marshall Wace LLP boosted its holdings in shares of MiMedx Group by 864.9% in the fourth quarter. Marshall Wace LLP now owns 1,381,288 shares of the company's stock valued at $9,351,000 after acquiring an additional 1,238,132 shares during the period. Disciplined Growth Investors Inc. MN grew its position in shares of MiMedx Group by 283.0% during the third quarter. Disciplined Growth Investors Inc. MN now owns 1,383,451 shares of the company's stock worth $9,656,000 after acquiring an additional 1,022,202 shares during the last quarter. Millennium Management LLC increased its holdings in shares of MiMedx Group by 93.9% in the 1st quarter. Millennium Management LLC now owns 1,230,984 shares of the company's stock valued at $9,355,000 after acquiring an additional 596,016 shares during the period. Finally, Ameriprise Financial Inc. increased its holdings in shares of MiMedx Group by 5,332.5% in the 2nd quarter. Ameriprise Financial Inc. now owns 559,058 shares of the company's stock valued at $3,416,000 after acquiring an additional 548,767 shares during the period. Institutional investors and hedge funds own 79.15% of the company's stock.</p>
<div class="lb-trans"><p>几家大型投资者最近调整了对 MDXG 的持股。Nantahala Capital Management LLC 在第三季度收购了 MiMedx Group 的新股份，价值约为 10,237,000 美元。Marshall Wace LLP 在第四季度将其在 MiMedx Group 的持股增加了 864.9%。Marshall Wace LLP 现在拥有 1,381,288 股公司股票，价值 9,351,000 美元，此前在该期间内又收购了 1,238,132 股。Disciplined Growth Investors Inc. MN 在第三季度将其在 MiMedx Group 的持股增加了 283.0%。Disciplined Growth Investors Inc. MN 现在拥有 1,383,451 股公司股票，价值 9,656,000 美元，此前在上个季度又收购了 1,022,202 股。Millennium Management LLC 在第一季度将其在 MiMedx Group 的持股增加了 93.9%。Millennium Management LLC 现在拥有 1,230,984 股公司股票，价值 9,355,000 美元，此前在该期间内又收购了 596,016 股。最后，Ameriprise Financial Inc.在第二季度将其在 MiMedx Group 的持股增加了 5,332.5%。Ameriprise Financial Inc.现在拥有 559,058 股公司股票，价值 3,416,000 美元，此前在该期间内又收购了 548,767 股。机构投资者和对冲基金持有公司 79.15% 的股份。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several analysts have recently issued reports on the company. Citigroup started coverage on MiMedx Group in a research note on Monday. They issued a &#34;market outperform&#34; rating on the stock. Mizuho reduced their price target on MiMedx Group from $12.00 to $10.00 and set an &#34;outperform&#34; rating on the stock in a research report on Wednesday, December 17th. Citizens Jmp began coverage on MiMedx Group in a research note on Monday. They issued a &#34;market outperform&#34; rating and a $10.00 price objective for the company. UBS Group set a $10.00 target price on shares of MiMedx Group in a research note on Monday. Finally, Wall Street Zen raised shares of MiMedx Group from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a report on Sunday, November 2nd. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $9.60.</p>
<div class="lb-trans"><p>几位分析师最近对该公司发布了报告。花旗集团在周一的研究报告中开始覆盖 MiMedx Group。他们对该股票给予了 “市场表现优于大盘” 的评级。瑞穗证券在 12 月 17 日的研究报告中将 MiMedx Group 的目标价从 12.00 美元下调至 10.00 美元，并对该股票给予了 “表现优于大盘” 的评级。Citizens Jmp 在周一的研究报告中开始覆盖 MiMedx Group。他们对该公司给予了 “市场表现优于大盘” 的评级，目标价为 10.00 美元。瑞银集团在周一的研究报告中对 MiMedx Group 设定了 10.00 美元的目标价。最后，华尔街 Zen 在 11 月 2 日的报告中将 MiMedx Group 的股票评级从 “买入” 上调至 “强力买入”。五位股票研究分析师对该股票给予了买入评级，一位分析师对该公司给予了持有评级。根据 MarketBeat，该股票的共识评级为 “适度买入”，平均目标价为 9.60 美元。</p>
</div><p><strong>View Our Latest Stock Report on MiMedx Group</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 MiMedx Group 股票报告</strong></p>
</div><h2>MiMedx Group Company Profile</h2>
<div class="lb-trans"><h2>MiMedx Group 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company's core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx's product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.</p>
<div class="lb-trans"><p>MiMedx Group, Inc 是一家生物制药公司，专注于开发、制造和营销源自人类胎盘组织的再生生物材料产品。公司的核心使命是利用羊膜和绒毛膜中的细胞外基质和生长因子来支持伤口愈合和外科应用。MiMedx 的产品线利用专有的净化工艺，旨在保留原生组织特性，同时确保无菌和安全。</p>
</div><p>MiMedx's principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.</p>
<div class="lb-trans"><p>MiMedx 的主要产品包括以 EpiFix®和 AmnioFix®等品牌命名的羊膜/绒毛膜同种异体移植物，适用于急性和慢性伤口的治疗，包括糖尿病足溃疡、静脉性腿部溃疡和手术部位修复。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than MiMedx Group</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>America’s 1776 happening again</li>
<li>This makes me furious</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 MiMedx Group 更好</li>
<li>华尔街害怕的黄金图表……</li>
<li>美国 1776 年再次发生</li>
<li>这让我感到愤怒</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=MDXG"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in MiMedx Group Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 MiMedx Group 吗？</h2>
</div><p>Before you consider MiMedx Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 MiMedx Group 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 MiMedx Group 并不在名单上。</p>
</div><p>While MiMedx Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 MiMedx Group 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

MiMedx 集团（NASDAQ:MDXG）公布季度财报，每股收益比预期高出 0.05 美元